Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ICCM - IceCure Medical Ltd.
Market Cap 54.29M P/E - EPS this Y 12.50% Ern Qtrly Grth -
Income -13.69M Forward P/E -4.25 EPS next Y 10.70% 50D Avg Chg 1.00%
Sales 3.34M PEG - EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 2.47 EPS next 5Y - 52W High Chg -75.00%
Recommedations 2.00 Quick Ratio 2.41 Shares Outstanding 49.52M 52W Low Chg 59.00%
Insider Own 54.18% ROA -47.36% Shares Float 22.69M Beta 2.67
Inst Own 0.73% ROE -94.22% Shares Shorted/Prior 393.09K/614.45K Price 1.19
Gross Margin 40.32% Profit Margin - Avg. Volume 163,838 Target Price 3.20
Oper. Margin -319.29% Earnings Date - Volume 85,366 Change 0.00%
Healthcare | Medical Devices | Israel
About IceCure Medical Ltd.

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

IceCure Medical Ltd. News
12/16/24 Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
12/05/24 IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
11/27/24 IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/26/24 IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
11/26/24 IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
11/25/24 IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
11/20/24 IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
11/19/24 IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
11/11/24 IceCure’s cryoablation system for breast cancer treatment gains FDA panel support
11/08/24 FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
10/29/24 Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
10/21/24 IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
10/10/24 Alignment HealthCare Partners With Intermountain Health in Nevada
10/07/24 IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
10/03/24 Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
07:15 AM IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
09/16/24 Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
09/12/24 IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
09/04/24 IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
08/28/24 USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies